Harmony Biosciences Holdings, Inc. (HRMY) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2025
Loading P/E history...
HRMY Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a price-to-earnings ratio of 12.1x, with a stock price of $32.78 and trailing twelve-month earnings per share of $2.70.
The current P/E is 66% below its 5-year average of 35.3x. Over the past five years, HRMY's P/E has ranged from a low of 8.7x to a high of 195.3x, placing the current valuation at the 21th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, HRMY trades at a 45% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, HRMY trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HRMY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HRMY P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 68.5 | - | +194% | |
| $2B | 6.8Lowest | 0.66Best | +817%Best | |
| $6B | 8.6 | - | +264% | |
| $4B | 9.4 | - | +68% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
HRMY Historical P/E Data (2021–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $37.42 | $2.71 | 13.8x | -61% |
| FY2025 Q3 | $27.56 | $3.18 | 8.7x | -75% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $31.60 | $3.10 | 10.2x | -71% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $33.19 | $2.62 | 12.7x | -64% |
| FY2024 Q4 | $34.41 | $2.51 | 13.7x | -61% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $40.00 | $2.11 | 19.0x | -46% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $30.17 | $1.95 | 15.5x | -56% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $33.58 | $2.31 | 14.5x | -59% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $32.30 | $2.12 | 15.2x | -57% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $32.77 | $2.46 | 13.3x | -62% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $35.19 | $3.27 | 10.8x | -70% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $32.65 | $3.10 | 10.5x | -70% |
Average P/E for displayed period: 35.3x
See HRMY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HRMY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HRMY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHRMY — Frequently Asked Questions
Quick answers to the most common questions about buying HRMY stock.
Is HRMY stock overvalued or undervalued?
HRMY trades at 12.1x P/E, below its 5-year average of 35.3x. At the 21th percentile of historical range, the stock is priced at a discount to its own history.
How does HRMY's valuation compare to peers?
Harmony Biosciences Holdings, Inc. P/E of 12.1x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is HRMY's PEG ratio?
HRMY PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2025.